​Helicore Biopharma Announces First Participant Dosed in Phase 1 Clinical Trial of
HCR-188, a First-in-Class GIP Antagonist for the Treatment of Obesity

January 28, 2025 - Press Release

​Helicore Biopharma Emerges from Stealth to Continue Advancing Portfolio of First-in-Class GIP Antagonists for Obesity and Related Conditions

​